HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

Hot Off The Press!

The Week in Review: Jan 13, 2017 – Jan 20, 2017

Friday, January 20, 2017 News Recap Lots of troubling news this last week.  From the Fut the Wuck department: Read this and Weep. Senior correctional officials at Correctional Service of Canada have made the decision not to provide clean drug-injection needles to prisoners to stem the spread of infectious disease because – are we ready? – doing so would make federal penitentiaries more dangerous places. Syringe needles could too easily be used as wea...

How the U.S. can beat hepatitis C: Don’t buy the pills, buy the company

In a recent article in Forbes, MIT Sloan School of Management visiting scientist Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer Center in New York, propose a startling response to the prevalence of hepatitis C and the high cost of the leading therapy: The U.S. government should not just pay for the pills — they should buy their maker. The pharmaceutical company Gilead sells hepatitis C drugs that have 80 percent

Blood victim finally told she is free of Hepatitis C – 29 years after becoming infected

Hello Canada:  This is what happens to a person who is cured of hepatitis C after 29 years of ravaging by the virus!!  Is anyone listening?  TREAT NOW! A victim of the contaminated blood scandal has been told she is now free of Hepatitis C – 29 years after she was given a transfusion. While she has to wait another six months to ensure no traces of the disease return, Michelle Tolley, 51, from Sparham said she is now “very hopeful”. The mother of fou

Strategies to address reimbursement restrictions for Hep C treatment: Lessons from Australia

Event Date: Monday February 6th 3-4:30pm EST Presented by: CATIE, CanHep C and The Kirby Institute Register here In Canada, direct-acting antiviral (DAA) hepatitis C treatments are costly, so provinces and territories limit access to patients based on fibrosis stage and other criteria such as HIV coinfection.  How can we move beyond this approach and achieve a model of access for all? This webinar, taking place February 6th, 3:00 p.m. ET, by...

Why are hepatitis C drugs priced so high? Click on the image BELOW to find out more!